Medical management of chronic pancreatitis

慢性胰腺炎的临床表现包括疼痛、脂肪泻和糖尿病。在西方国家，慢性胰腺炎最常见的病因是酗酒。70％以上的病人在就诊时有疼痛的临床表现，而且，这些患者中又有75％以上会在几年之后出现疼痛减轻或完全消失。对于所有的慢性胰腺炎的病人来说，均应排除非胰源性疼痛和胆道梗阻、胰腺假性囊肿等胰腺局部并发症。应建议所有慢性胰腺炎病人戒烟、戒酒。阿片类镇痛剂仅应用于治疗疼痛严重的病人。尽管有报道认为胰酶替代治疗有助于止痛，但是，对于已经确诊的慢性胰腺炎病人来说，该疗法无效。激素类药物进行腹腔神经丛阻滞术可能有助于病人度过剧烈疼痛期。顽固性疼痛是进行胰液引流或胰腺切除的适应证。建议应用适量胰酶替代联合(或不联合)制酸剂治疗营养不良。慢性胰腺炎导致的糖尿病与原发性糖尿病的治疗原则相似。     

脂肪乳剂在重症急性胰腺炎营养治疗中的安全性及有效性分析

目的 :探讨脂肪乳剂应用于重症急性胰腺炎的安全性和有效性。　方法 :回顾分析重症急性胰腺炎病人肠外营养治疗期间 ,应用脂肪乳剂的影响。 74例重症急性胰腺炎病人行肠外营养治疗 ,按静脉营养液是否含脂肪乳剂分为脂乳组和非脂乳组。　结果 :脂乳组肠外营养治疗后清蛋白、前白蛋白改善显著 (P <0 .0 1 ) ,非脂乳组则无显著变化 (P >0 .0 5 ) ,脂乳组较非脂乳组改善明显 (P <0 .0 1 ) ;血清肌酐、尿素氮等在脂乳组治疗后下降明显 (P <0 .0 5 ) ,较非脂乳组改善显著 (P <0 .0 5 ) ;营养治疗结束后 ,脂乳组高血糖症状明显得到控制 (P <0 .0 1 ) ,而非脂乳组效果不佳 (P >0 .0 5 ) ,脂乳组优于非脂乳组 (P <0 .0 5 ) ;血淀粉酶均有下降 ,脂乳组未见异常增高。　结论 :重症急性胰腺炎病人输注脂肪乳剂安全有效 ,有助于恢复正氮平衡     

Hepatic infarction with portal thrombosis

A case of hepatic infarction with portal thrombosis is reported. A 63-year-old woman with liver cirrhosis and esophageal varices was admitted for treatment of the esophagel varices. Endoscopic variceal ligation (EVL) and endoscopic injection sclerotherapy (EIS) were performed. Two months later, she experienced right hypochondralgia and right flank pain. Serum transaminase levels were suddenly elevated, and computed tomography scans of the liver showed multiple small nodular lesions. Her condition worsened, and she died of hepatic failure. Autopsy revealed splenic and portal vein thrombosis, multiple hepatic infarction, and evidence of chronic pancreatitis. We believe that liver cirrhosis and chronic pancreatitis were the main risk factors for the portal thrombosis, and the treatment for esophageal varices appeared to have triggered the thrombosis. The hepatic infarction was caused by the portal thrombosis.     

桂美辛和山莨菪碱治疗胆绞痛的比较

桂美辛组(男性21例,女性35例;年龄44±12a)治疗胆绞痛56例,剂量300mg, po, tid,显效32例,有效21例,总有效率95％。山茛菪碱组52例(男性18例,女性34例;年龄46±13a),剂量10mg, im, tid,显效、有效分别为9与20例,总有效率56％。2组比较,P<0.01。桂美辛治疗胆绞痛有疗效高、不良反应少的优点。     

Endoscopic sphincterotomy for common bile duct stones: Impact of recent technical advances

Technical improvements, such as mechanical lithotripsy, stenting or nasobiliary drainage, and wire-guided cannulation, have reduced the risk of complications in endoscopic sphincterotomy. To determine the extent of this reduction in risk, we assessed the medical records of 1352 patients with common bile duct stones in whom the procedure was conducted. Complications examined were: acute cholangitis and pancreatitis. Stone clearance was achieved in 1256 patients (92.8%), with an overall morbidity rate of 7.7% and a mortality rate of 0.15%. One hundred and forty-two patients had stones with a diameter greater than 20mm; 97 of these patients did not undergo lithotripsy. Cholangitis occurred in 10 of these 97 patients (10.3%), whereas, in the 45 patients who underwent lithotripsy, there were no cases of cholangitis (P=0.02). Stone removal was not immediately accomplished or attempted in 396 patients. In 82 of these patients in whom a stent or a nasobiliary drain was placed in the common bile duct, the incidence of cholangitis was 1.2%, significantly less (P=0.045) than the incidence of 6.4% in the other 314 patients given no stenting or nasobiliary drain. To overcome difficult cannulation, precut sphincterotomy was conducted in 134 patients and wireguided sphincterotomy, a recently introduced procedure, was conducted in 55 patients. When the precutting technique was used, the incidence of acute pancreatitis was significantly higher (8/134; 6.0%) than that in the patients in whom the standard procedure was conducted, i.e., neither the precut technique nor wire-guided ES was used (23/1218; 1.9%) (P=0.008). There were no cases of pancreatitis in the 55 patients in whom wire-guided sphincterotomy was performed, although the difference was not statistically significant because of the small number of patients (P=0.06). Based on these findings, we conclude that improved technologies have led to a significant reduction of complications in endoscopic sphincterotomy.     

Laparoscopic gastrojejunostomy and endoscopic biliary stent placement for palliation of incurable gastric outlet obstruction with cholestasis

Background: For patients with incurable malignant gastric outlet obstruction and cholestasis, laparoscopic gastrojejunostomy combined with endoscopic biliary stent placement seems to offer a minimally invasive palliation. Methods: We retrospectively analyzed the data of 16 patients submitted to laparoscopic gastrojejunostomy. Laparoscopic gastroenterostomy was performed as an antecolic, side-to-side gastrojejunostomy with enteroenterostomy. In 12 patients cholestasis was relieved preoperatively by stent placement via endoscopy (n= 6, 37.5%), percutaneous access (n= 5, 31%) or bilioenteric anastomosis (n= 1, 6.25%). One patient needed a percutaneous Yamakawa prosthesis postoperatively. Results: Mean operative time was 126 min. There were no intraoperative complications. In one patient conversion to open surgery became necessary because of extensive adhesions. The only postoperative complication was bleeding from a trocar site requiring reintervention; there was no mortality. Median postoperative hospital stay was 7 days. Delayed gastric emptying was observed in 3 (18.7%) patients. Median survival was 87 days after the operation. All patients died from their primary disease but could maintain oral intake during the remaining survival time. Conclusions: We conclude that laparoscopic gastrojejunostomy and endoscopic or percutaneous biliary stenting provide a good functional result while impairing the quality of life only to a minimal extent. Received: 7 May 1996/Accepted: 12 December 1996     

急性重症胰腺炎中转手术时机探讨

目的 探讨非手术治疗急性重症胰腺炎中转手术的时机及指征。方法 回顾分析1991年5月～2003年12月我科收治的308例急性重症胰腺炎患者的并发症发生率、死亡率及中转手术情况。结果 治愈284例(92．2％)，死亡24例(7．8％)。治疗过程中109例出现并发症，其中胰腺坏死组织继发感染12例，胰腺假性囊肿52例，多器官功能损害或衰竭24例，单个器官功能损害27例。中转手术23例(7．5％)，其中行胰腺坏死组织清除12例，胰腺假性囊肿感染引流2例，腹腔引流5例，胰腺脓肿引流1例，因急性坏死性胆囊炎和急性化脓性胆囊炎行胆道手术各1例，穿孔修补 胰包膜减压术1例。结论 急性重症胰腺炎早期采取积极的非手术治疗可获得满意的效果；对在非手术治疗过程中出现胰腺感染、不能控制的胆道感染、病情无好转且进行性恶化者或有其他外科并发症者及时中转手术，可望提高急性重症胰腺炎的治愈率。     

肝细胞生长因子对实验性急性胰腺炎细胞凋亡作用的研究

目的:观察外源性肝细胞生长因子(HGF)对小鼠轻症实验性急性胰腺炎的炎症反应及胰腺细胞凋亡的作用。方法:以雨蛙肽腹腔注射诱发小鼠轻症实验性急性胰腺炎。第1组以盐水腹腔注射作为对照,第2、3及4组每小时腹腔注射雨蛙肽诱发急性胰腺炎;第3组在造模前及造模中两次皮下注射重组人肝细胞生长因子(rhHGF);第4组同时皮下注射rhHGF及其单抗。观察HGF对炎症反应的干预作用及对腺泡细胞凋亡的影响。结果:炎症小鼠予每公斤体重4、20μgrhHGF时,与单纯炎症组相比,血清淀粉酶、脂肪酶下降,胰腺组织学炎症评分减少,胰腺腺泡细胞TUNEL凋亡指数增加,caspase3活性增强。予每公斤体重4或20μgrhHGF时,其效应无显著性差异。同时予rhHGF单抗的小鼠,上述指标与单纯炎症组相比差异无显著性。结论:HGF能减轻雨蛙肽诱导的小鼠轻症实验性急性胰腺炎。HGF单抗能消除HGF的生物学作用。HGF可以促进急性胰腺炎时腺泡细胞的凋亡,这可能是其保护胰腺的作用机制之一。     

重症急性胰腺炎合并深部真菌感染的治疗经验

为分析重症急性胰腺炎(SAP)合并深部真菌感染的临床特点、危险因素及预后,并探讨其防治的策略,回顾性分析85例SAP合并感染的临床资料,其中43例合并真菌感染,42例为单纯细菌感染。研究发现2组的年龄、性别、病因、ICU住院时间均无显著性差异;真菌感染组较细菌感染组APACHE Ⅱ评分及CT分级高,发生菌群紊乱、腹压增高及器官障碍的概率高、手术次数多,且均有显著性差异。真菌组的病死率约是细菌组的2倍多(44.19％比21.43％)。结果提示:合并真菌感染病死率明显增高;APACHE Ⅱ评分、CT分级、菌群紊乱、腹压增高、手术次数是真菌感染发生的危险因素;当发现不明原因的发热、意识改变及大出血时应怀疑合并真菌感染的可能;预防性抗真菌药物的应用可能有助于防治真菌感染。